SCM
CPRX

Sterling Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Sterling Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.2K Sell
2,190
-825
-27% -$19.7K ﹤0.01% 1603
2025
Q4 		$70.4K Buy
3,015
+2,735
+977% +$60.9K ﹤0.01% 1667
2025
Q3 		$5.52K Hold
280
– – ﹤0.01% 2743
2025
Q2 		$6.08K Buy
280
+163
+139% +$3.85K ﹤0.01% 2417
2025
Q1 		$2.84K Buy
117
+4
+4% +$90 ﹤0.01% 2436
2024
Q4 		$2.36K Hold
113
– – ﹤0.01% 2739
2024
Q3 		$2.25K Buy
+113
New +$2.1K ﹤0.01% 2134

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sterling Capital Management's CPRX Position: Q1 2026 in Review

Sterling Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 27% in Q1 2026, selling an estimated $19.7K and leaving 2,190 shares worth $54.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Sterling Capital Management first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $70.4K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Sterling Capital Management held 2,190 shares of Catalyst Pharmaceutical worth $54.2K as of Q1 2026.
  • Sterling Capital Management sold 825 Catalyst Pharmaceutical shares in Q1 2026, an estimated $19.7K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1603 holding.
  • Sterling Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Catalyst Pharmaceutical position peaked at $70.4K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.